SynthesisBMJ (Clinical research ed.)2005
Angiotensin receptor blockers and risk of myocardial infarction: systematic review.
Synthesis in BMJ (Clinical research ed.), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis.European journal of clinical pharmacology · 2011Pooled it
- Article
- Effects of oral losartan administration on homeostasis of articular cartilage and bone in a rabbit model.Bone reports · 2022Article
- Effect of Amlodipine in Stroke and Myocardial infarction: A Systematic Review and Meta-analysis.Cardiology and therapy · 2021Review
- COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies.Molecular biology reports · 2021Review
- The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.Journal of clinical hypertension (Greenwich, Conn.) · 2016Observational
- The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.Drug safety · 2015Review
- RAAS inhibition and mortality in hypertension.Global cardiology science & practice · 2013Review
- Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.Heart and vessels · 2011Article
- A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.Vascular health and risk management · 2011Review
- Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.Vascular health and risk management · 2010Review
- Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.Atherosclerosis · 2010Review
- Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.Clinical drug investigation · 2010Review
- Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.Clinical drug investigation · 2009Article
- Uncertainty in heterogeneity estimates in meta-analyses.BMJ (Clinical research ed.) · 2007Review
- Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.Clinical drug investigation · 2007Review
- Review
- BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.Clinical drug investigation · 2007Article
- Drug therapy for the secondary prevention of stroke in hypertensive patients: current issues and options.Drugs · 2007Review
- Angiotensin inhibition after myocardial infarction: does drug class matter?Journal of general internal medicine · 2006Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of angiotensin receptor blockers on the risk of myocardial infarction in patients at risk for cardiovascular events.
designSystematic review of controlled trials of angiotensin receptor blockers. DATA SOURCES: Medline, Embase, Cochrane central register of controlled trials, hand search, and contact with investigators. SELECTION OF STUDIES: Predefined criteria were used to select controlled clinical trials comparing use of angiotensin receptor blockers with angiotensin converting enzyme (ACE) inhibitors or placebo in patients at risk for cardiovascular events. Data were extracted for patients' characteristics, interventions, quality of trials, and rates of myocardial infarction.
results19 studies with 31,569 patients were included in the analysis. Two studies investigated the use of angiotensin receptor blockers in hypertensive patients, four studies in patients with diabetes and nephropathy, 10 studies in patients with heart failure, and three in patients with recent myocardial infarction or ischaemic syndrome. 11 studies of 21,062 patients allowed for comparison between angiotensin receptor blockers and placebo; nine studies of 10,625 patients allowed for comparison between angiotensin receptor blockers and ACE inhibitors. Use of angiotensin receptor blockers was not associated with increased risk of myocardial infarction compared with placebo (odds ratio 0.94, 95% confidence interval 0.75 to 1.16) nor with increased risk of myocardial infarction compared with ACE inhibitors (1.01, 0.87 to 1.16).
conclusionsTreatment with angiotensin receptor blockers was not associated with a significantly increased risk of myocardial infarction. The 95% confidence intervals do, however, not exclude an increase of up to 16% in the risk of myocardial infarction or a reduction in risk of up to 25%. Until further information specifically dealing with this issue is available from large prospective trials, our findings may alleviate recent concerns over the safety of this class of medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.